The Middle East Health Journal
SEE OTHER BRANDS

Catch up with healthcare and wellness news from the Middle East

The Middle East Health Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.

Press releases published on April 24, 2025

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare …

Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting

Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting

CUPERTINO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of …

X4 Pharmaceuticals Announces Reverse Stock Split

X4 Pharmaceuticals Announces Reverse Stock Split

BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that its board of directors has determined to effect a one-for-thirty …

Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas

Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas

MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and Enable Medicine, a real-world data company providing AI-ready patient, cellular and molecular data, today announced a …

Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025

Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025

MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, today announced the availability of a new assay designed to advance antibody-drug conjugate (ADC) development in breast cancer. The …

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

April 28th AUA data presentation to highlight study in patients with high-grade non-muscle invasive bladder cancer (HG-NMIBC) Virtual event to be held on April 28, 2025 at 4:30 PM ET CORAL GABLES, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Relmada …

Autonomize AI Prior Authorization Copilot: Helping Patients Get Care Faster, Safer, and with Less Stress

Autonomize AI Prior Authorization Copilot: Helping Patients Get Care Faster, Safer, and with Less Stress

AUSTIN, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Autonomize AI, the leader in healthcare-native AI, today announced a major update to its Prior Authorization Copilot that is delivering rapid, patient-centered improvements across U.S. health plans. The …

ORYZON Raises €30 Million in Capital Increase

ORYZON Raises €30 Million in Capital Increase

Issued 12,765,958 new shares Priced at €2.35 per share, representing a 15.44% discount on the 5-day VWAP Strong investor demand, with the offering significantly oversubscribed €15 million anchored by a leading US institutional investor Proceeds to fund …

ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status

ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status

WESTON, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who …

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised animals from a lethal challenge with clade IIa monkeypox virus Durability of TNX-801 vaccination shown by six-month …

Nerve Renew Under Review & Ingredients Guide | Best Nerve Pain Supplement Explained

Nerve Renew Under Review & Ingredients Guide | Best Nerve Pain Supplement Explained

Eagle, Idaho, April 24, 2025 (GLOBE NEWSWIRE) -- There are some occurrences inside the human body that remain a mystery to the medical community. Nerve discomfort is among these mysteries. Knowing that the pain in the fingers, legs, and feet is caused by …

Tonic Greens Review: Will TonicGreens Supplement Work for Immune Support? Read Tonic Greens Official Report!

Tonic Greens Review: Will TonicGreens Supplement Work for Immune Support? Read Tonic Greens Official Report!

Aurora, Colorado, April 24, 2025 (GLOBE NEWSWIRE) -- Lack of immunity is the leading cause of all health problems. It may be caused by age, environmental pollutants, genetic abnormalities, and other reasons. Nature has a remedy, and employing it correctly …

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

(IMAGES BELOW) Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor positive (HR+) breast cancer patient Treatment well-tolerated and patient remains on study with stable disease elsewhere Sustained clinical response …

Kura Oncology to Report First Quarter 2025 Financial Results

Kura Oncology to Report First Quarter 2025 Financial Results

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will …

Ace Vision Group Announces Initial Close of $29.4 Million Series B Financing Round

Ace Vision Group Announces Initial Close of $29.4 Million Series B Financing Round

Funding supports the commercial product development of VisioLite® Device and Laser Scleral Microporation Human Clinical Study. Capital raised to date provides strong financial position to prepare the device for regulatory trials and submissions. BOSTON, …

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

- Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned for late 2025 - WALTHAM, Mass., April 24, 2025 (GLOBE …

Amwell® to participate in upcoming investor conferences

Amwell® to participate in upcoming investor conferences

BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will participate in the following upcoming investor conferences:   On May 8, Mark …

Avidicure Launches with $50 Million in Seed Financing to Develop New Multifunctional Antibody Modality to Treat Cancer

Avidicure Launches with $50 Million in Seed Financing to Develop New Multifunctional Antibody Modality to Treat Cancer

AVC-Boosters are designed as dual agonistic antibodies to safely deliver targeted and potent monotherapy with broad application in oncology Lead product AVC-S-101 is a TROP2-targeting booster being developed for non-small cell lung cancer and multiple …

SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago

SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago

Two PROTAC synergy using two E3 ligases for achieving levels of degradation of KRAS G12D not achieved with single PROTACs, will be presented by the lab of Luca Busino, PhD, from the University of Pennsylvania, on April 27th SEED’s first IND candidate …

Mitolyn Reviews 2025: Why This Non-Stimulant Best Weight Loss Supplement Is a Game-Changer for Fat Burn and Metabolism

Mitolyn Reviews 2025: Why This Non-Stimulant Best Weight Loss Supplement Is a Game-Changer for Fat Burn and Metabolism

Tallmadge, Ohio, April 24, 2025 (GLOBE NEWSWIRE) -- As more health-conscious individuals seek safer, stimulant-free alternatives for weight management in 2025, natural supplements are becoming the gold standard. Crash diets, intense fitness programs, and …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service